**THU0205**

**THE HEMATOPOIETIC STEM CELLS (HSCs) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): REPROGRAM THEIR TRANSCRIPTOME: IMPLICATIONS FOR THE PATHOGENESIS OF THE DISEASE**

Angelos Banos1, Maria Grigorou1, Anastasia Filia1, Pavlos Pavlidis2, Lina Giannouli3, Vassiliki Karali4, Dionisis Nikolopoulos1, Antigoni Pieta1, Ioannis Mitroulis5, Panayotis Verginis1, Dimitris Bourmpas3, 1Biomedical Research Foundation of the Academy of Athens, Laboratory of Immune Regulation and Tolerance, Athens, Greece; 2Foundation for Research and Technology-Hellas, Institute of Computer Science, Heraklion, Greece; 3National and Kapodistrian University of Athens, 2nd Department of Medicine, Ippokration University Hospital, Athens, Greece; 4National and Kapodistrian University of Athens, 4th Department of Medicine, Attikon University Hospital, Athens, Greece; 5Democritos University of Thrace, Laboratory of Molecular Hematology, Department of Medicine and First Department of Internal Medicine, University Hospital of Alexandroupolis, Alexandroupolis, Greece

**Background:** In SLE, all terminally differentiated blood cells demonstrate an aberrant phenotype. HSCs are the most primitive cell type of the hematopoietic lineage when exposed within the bone marrow (BM) to adjuvants and inflammatory mediators change their transcriptional landscape and this may persist in the HSCs circulating in the peripheral blood or those infiltrating peripheral tissues. Within peripheral tissues these reprogrammed HSCs differentiate into myeloid cells mounting enhanced protective or aberrant immune responses. *Objective:* To dissect whether aberrant phenotypes of blood cells in SLE could be traced back to HSCs and explore how the inflammatory environment of SLE shapes the HSC differentiation process.

**Methods:** We analyzed the transcriptional alterations (genetic or epigenetic) of CD34+ cells in the BM of SLE patients, compared it to healthy individuals and the NZB/W lupus mice at the onset of disease (6 months). CD34+ cells were isolated from BM aspirates and peripheral blood of SLE patients (n=6) and healthy subjects (n=2) with magnetic separation (Stem Cell Technologies). mRNA was extracted and libraries were prepared. Sequencing was performed in NextSeq Illumina Platform. Alignment in human genome v3.8 was done by Star package and differential expression analysis was performed by edgeR algorithm. Genes with FDR <1.5% and log2(FDR) = 0.05 were considered statistically significantly up/down-regulated, respectively. Heatmaps were constructed in R, GOPathway Analysis and enrichment analysis were performed in ClueGo, RNEA, GeneMania and GSEA, respectively.

**Results:** Overlaying the transcriptome of BM-derived CD34+ of SLE patients and healthy subjects, we identified in total 598 differentially expressed genes (DEGs) (82 up-514 down-regulated in SLE). DEGs participate in hematopoietic cell lineage fate, regulation of stem cell differentiation, cell adhesion and cell cycle regulation. We also found evidence for cell cycle checkpoints signatures which drive HSCs to experience replication stress and activate ATR pathway. Comparison of CD34+ profile between severe-moderate SLE reveals a prominent neutrophilic signature in severe disease. Comparative transcriptomic analysis of human vs murine SLE revealed a panel of common genes again related to cell proliferation, differentiation and platelet activation.

**Conclusion:** HSCs in SLE patients and murine lupus reprogram their transcriptome in response to the inflammatory milieu within the BM, thus exiting from dormancy, differentiating to myeloid cells and mounting a DNA damage response to the replication stress. This activated phenotype renders HSCs both susceptible to cell exhaustion while at the same time priming them and their progenies towards enhanced immune responses.

**REFERENCES:**


**Acknowledgement:** This work was supported by FOREUM, IKY and ERC-Advanced Grant.

**Disclosure of Interests:** None declared


---

**THU0206**

**ANTI-D4GDI ANTIBODIES ACTIVATE PLATELETS IN VITRO: A POSSIBLE LINK WITH THROMBOCYTOPENIA IN PRIMARY ANTIPHOSPHOLIPID SYNDROME**

cristiana barcati, Lucia Stefanini, Tania Colasanti, Enrica Cipriano, Alessandra Ida Ceia, Gianna Gabriela, Marta Vemero, Fulvia Cecarelli, Francesca Spinelli, Annacarla Finucci, Annacarla FinucciGiovanni Orso, Carlo Perricone, Mariangela Speziali, Asialessandro, sapienza università di roma, dipartimento di medicina interna e specialità mediche, Rome, Italy

**Background:** Thrombocytopenia is a manifestation associated with Primary Antiphospholipid Syndrome (PAPS) and many studies have stressed the leading role played by platelets in the pathogenesis of Antiphospholipid Syndrome (APS). 1. Platelets are highly specialized cells and their activation is a key event in the regulation of vessel permeability. 2. Recently, we described the presence of autoantibodies against D4GDI (Rho GDP Dissociation Inhibitor Beta, ARHGDIB) in the serum of a large subset of SLE patients and we observed that anti-D4GDI antibodies activated the cytoskeleton remodeling of lymphocytes by inhibiting D4GDI and allowing the upregulation of Rho GTPases, such as Rac1(3). Proteomic and transcriptomic studies indicate that D4GDI is very abundant in platelets and small GTPases of the Rho family are critical regulators of actin dynamics in platelets (4).

**Objectives:** The aim of the present study was to evaluate the presence of anti-D4GDI antibodies in PAPS sera and whether they can affect platelet activation, contributing to the thrombotic events and the thrombocytopenia of PAPS patients.

**Methods:** 38 PAPS patients diagnosed according to the 2006 Sydeny classification criteria were enrolled from the Lupus Clinic of the Sapienza University of Rome. 20 normal healthy subjects (NHS) served as controls. Sera were stored at −20°C to perform an ELISA test using comercial D4GDI protein. Anti-D4GDI antibodies were purified from PAPS sera and used for in vitro treatment of platelets purified from NHS. Flow cytometry analysis was performed to determine of integrin αIIbβ3 activation, a well-established marker of platelet activation and adhesion.

**Results:** We identified anti-D4GDI antibodies in sera from 18/38 (47%) patients with PAPS, but in no sera from NHS. Dividing the patients with PAPS according to the presence or absence of thrombocytopenia, we found a significant association between this hematologic manifestation and a higher titer of anti-D4GDI antibodies. Our in vitro results show a significant 30% increase in the activation of integrin αIIbβ3 upon stimulation of platelets from healthy donors preincubated with the antibody anti-D4GDI purified from the serum of APS patients. Interestingly the antibody does not only increase the overall integrin activation but also the rate/speed of integrin activation.

**Conclusion:** We demonstrated that antibodies anti-D4GDI are present in the sera of PAPS patients and can prime platelet activation. Thus, explaining, at least in part, the pro-thrombotic state and the thrombocytopenia of PAPS patients. These findings may lead to improved diagnosis and treatment ofAPS.

**REFERENCES:**


**Disclosure of Interests:** None declared